A
4.41
0.13 (3.04%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Alto Neuroscience, Inc. | 看跌 | - |
AIStockmoo 评分
-0.8
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.75 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 7.51% |
| 机构持股比例 | 91.30% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Alpha Wave Global, Lp | 30 Sep 2024 | 3,707,757 |
| Ra Capital Management, L.P. | 30 Sep 2024 | 2,075,154 |
| 72 Investment Holdings, Llc | 30 Sep 2024 | 667,778 |
| Vestal Point Capital, Lp | 30 Sep 2024 | 650,000 |
| Awm Investment Company, Inc. | 30 Sep 2024 | 559,731 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 18.00 (Jones Trading, 308.16%) | 购买 |
| 中 | 10.00 (126.76%) | |
| 低 | 4.00 (Wedbush, -9.30%) | 保留 |
| 平均值 | 10.50 (138.10%) | |
| 总计 | 3 购买, 1 保留 | |
| 平均价格@调整类型 | 4.25 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Jones Trading | 16 Dec 2024 | 18.00 (308.16%) | 购买 | 3.75 |
| Stifel | 13 Nov 2024 | 10.00 (126.76%) | 购买 | 4.53 |
| Baird | 23 Oct 2024 | 10.00 (126.76%) | 购买 | 4.36 |
| Wedbush | 23 Oct 2024 | 4.00 (-9.30%) | 保留 | 4.36 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合